

Review article:

ENHANCING CANCER CARE WITH IMPROVED CHECKPOINT
INHIBITORS: A FOCUS ON PD-1/PD-L1

Vickram A S^{1*}, Saghya Infant Shofia¹, A. Saravanan¹, Vidhya Lakshmi Sivakumar¹,
Packiyam Thamarai¹, Manikandan Sivasubramanian¹, Shivani Chopra²,
Hitesh Chopra³

¹ Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of
Medical and Technical Sciences, Chennai, India

² Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical
and Technical Sciences, Chennai - 602105, Tamil Nadu, India

³ Center for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara
University, Rajpura, 140401, Punjab, India

* **Corresponding author:** Vickram A S, Department of Biotechnology, Saveetha School
of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, India.
E-mail: vickramas.sse@saveetha.com

<https://dx.doi.org/10.17179/excli2024-7783>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(<http://creativecommons.org/licenses/by/4.0/>).




Figure 1: Graphical abstract

ABSTRACT

The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm shift in cancer therapy, offering a novel avenue for enhancing patient outcomes. This review examines the structural and functional dynamics of PD-1 and PD-L1 while exploring the clinical implications of current PD-1/PD-L1 monoclonal antibodies. Highlighting recent advancements, this paper delves into the promising results from combination therapies that present a multifaceted attack on tumor progression. Despite the success observed across various cancer types, challenges such as immune resistance remain. Future considerations are discussed with an emphasis on the need for further clinical studies, aiming to refine and broaden the curative potential of PD-1/PD-L1 inhibitors in oncology. This review postulates that ongoing research and innovative approaches could significantly enhance cancer care, making immunotherapy an even more central strategy in the fight against cancer.

Keywords: Checkpoint inhibitors, PD-1, PD-L1, cancer, immunotherapy

THE PARADIGM SHIFT IN CANCER THERAPY WITH CHECKPOINT INHIBITORS

For decades, traditional methods of cancer treatment like surgery, chemotherapy, and radiation have held the upper hand in the world of cancer therapy. While each has its own merits and drawbacks, their primary aim has been to directly eliminate cancer cells, often with repercussions for healthy tissue and serious side effects for patients. In recent times, a significant shift has occurred, marking a new era in the fight against cancer: the emergence of immune checkpoint inhibitors. These therapies harness the power of our body's immune system to combat cancer, bringing a fresh perspective to the table (Maawy and Ito, 2019; He and Xu, 2020).

The development of these groundbreaking medications has completely transformed the world of cancer treatment, revolutionizing the way we combat the disease. With these innovative drugs, we can now harness the power of the immune system to fight cancer more efficiently and with greater consideration for the patient's well-being (Ribas and Wolchok, 2018). A crucial component in this breakthrough is the understanding of immune checkpoints - molecules within the immune system that can either intensify a signal (known as co-stimulators) or weaken a signal (known as co-inhibitors). Unfortunately, cancer cells often exploit these checkpoints, evading detection and attack from the body's own immune cells (Dine et al., 2017; Darwin et al., 2018).

An exciting finding in the field of cancer immunotherapy has been the identification of immune checkpoints, particularly CTLA-4 and PD-1/PD-L1, which serve as key regulators in protecting tumors from immune attacks (Qin et al., 2019). This groundbreaking discovery has paved the way for the development of monoclonal antibodies known as checkpoint inhibitors, designed to target these proteins and disable their "off" signals. By doing so, these inhibitors empower the immune system to recognize and eliminate cancer cells (Shiravand et al., 2022).

The recent development and usage of drugs aiming at PD-1 and PD-L1 have brought about monumental breakthroughs in the management of various cancers, such as melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, and head and neck cancers (Lee et al., 2022). These successes are abundant, as patients have seen remarkable and sustained remissions, along with a significant boost in their chances of survival. However, this progress has not come without hurdles and obstacles to overcome (Wang et al., 2021).

The immune landscape and tumor micro-environment are complex and not all patients are affected in the same way by checkpoint inhibitors. As a result, there has been a surge of research aimed at unravelling the reasons behind resistant tumors and discovering biomarkers that can accurately forecast the individuals most likely to benefit from these therapies (Larkin et al., 2019). Despite these challenges, the remarkable clinical efficacy of checkpoint inhibitors has sparked a renaiss-

sance in the field of oncology. These treatments not only enhance survival rates for specific cancers, but also provide a better quality of life for numerous patients by minimizing side effects when compared to traditional therapies (Barrueto et al., 2020).

Exploring the intricacies of molecular and cellular processes, scientists have uncovered the inner workings of checkpoint pathways and their vital role in immune regulation (Shao et al., 2023). Among the various types of immune cells, T cells possess the remarkable ability to selectively seek out and eliminate cancerous cells. However, in the presence of a tumor, these cells can become suppressed and "exhausted" by inhibitory signals (Sun et al., 2023a). To counteract this, inhibitors targeting key checkpoints such as PD-1/PD-L1 and CTLA-4 have emerged as crucial tools in the field of immuno-oncology, effectively reactivating these exhausted T cells (Immuno-oncology checkpoint inhibitors, 2022).

The continuous improvement of these medications has been greatly aided by advancements in genetic sequencing and bioinformatics. This enables a more personalized and tailored approach to treatment. By delving into the genetic composition of a patient's tumor, there is potential to anticipate their response to checkpoint inhibitor therapy. This leads to the creation of individualized and efficient care plans, as demonstrated by the research (Sun et al., 2023b). Moreover, the incorporation of checkpoint inhibitors with other forms of treatment, such as targeted therapies, chemotherapy, and radiation, has resulted in a powerful synergy. This has shown to be more effective in addressing cancer than utilizing any single therapy alone (Li et al., 2023).

As we observe the ongoing evolution of checkpoint inhibitors, scientists are delving into innovative avenues to develop the next generation of these medicines, striving to bolster their effectiveness, overcome barriers to treatment, and minimize negative consequences (Li et al., 2019a). Ongoing clinical studies are actively investigating combination

therapy approaches, alternative dosing methods, and novel targets that go beyond the traditional PD-1/PD-L1 and CTLA-4 pathways (Yi et al., 2022).

The use of checkpoint inhibitors marks a groundbreaking change in cancer treatment, but we are only at the start of this revolution. This breakthrough opens the door to a promising new era in medicine, where harnessing the power of the immune system can potentially overcome cancer. As science progresses and more individuals reap the benefits of these innovative therapies, the ultimate aim is to make checkpoint inhibitors a commonplace and essential aspect of cancer care. The goal is to provide patients with longer, healthier lives, and transform what was once feared as an insurmountable disease into something manageable or even curable.

Chang et al. (2021) reviewed FDA approvals of PD-1/PD-L1 inhibitors over six years, examining the reasons for approval, regulatory pathways, and use of companion diagnostics. They emphasized the efficacy of these drugs while noting the moderate response rates and the need for more research (Table 1). Chen et al. (2021) conducted a meta-analysis of 91 clinical trials to assess the effectiveness of PD-1/PD-L1 inhibitors in various clinical scenarios, quantifying overall response rate, time to response, and duration of response across different cancers, treatment lines, drug combinations, and regimens. Zhang et al. (2024) performed a meta-analysis of 69 randomized controlled trials to investigate cardiovascular toxicity risks associated with PD-1/PD-L1 inhibitors in solid tumors, finding elevated risks of hypertension, hypotension, arrhythmia, and myocarditis, especially when combined with chemotherapy or CTLA-4 inhibitors. Finally, this current review offers a comprehensive overview of PD-1/PD-L1 inhibitors, encompassing their mechanism of action, clinical implications, combination therapies, challenges such as immune resistance, and future research directions, with a focus on the potential of combination therapies and a qualitative analysis of their mechanisms and clinical impact.

Table 1: FDA-approved immune checkpoint inhibitors and their indications across various tumor types

Tumor Type	Therapeutic Agent	FDA Approval Year	Target	FDA-Approved Indications	Additional Information	References
Melanoma	Ipilimumab	2011	CTLA-4	Stage 3 or 4 malignant melanoma	Associated with immune-related adverse events. Explored in combination with targeted therapies	Mansh, 2011
Melanoma	Nivolumab	2014	PD-1	Stage III-B or IV Squamous NSCLC	Ongoing research in combination therapies. Promising results in real-world evidence studies	Rolfo et al., 2017
Melanoma	Pembrolizumab	2014	PD-1	Stage IV nonsquamous and squamous NSCLC	Notable response rates in patients with high PD-L1 expression. Explored in adjuvant settings	Wu et al., 2021
Non-small cell lung cancer	Nivolumab	2015	PD-1	Stage III non-small-cell lung cancer (NSCLC)	Under investigation for early-stage lung cancer. Combined with chemotherapy in unresectable disease	Paz-Ares et al., 2020
Non-small cell lung cancer	Pembrolizumab	2015	PD-1	Nonsquamous NSCLC	Effective in patients with high tumor mutational burden. Investigated in elderly populations	Rocco et al., 2022
Melanoma (BRAF wild-type)	Ipilimumab + Nivolumab	2015	CTLA-4, PD-1	Stage III-B or IV Melanoma (BRAF wild-type)	Investigated for neoadjuvant treatment in clinical trials. Associated with improved overall survival	Mazieres et al., 2020
Melanoma (adjuvant)	Ipilimumab	2015	CTLA-4	Adjuvant treatment for melanoma	Investigated in brain metastases	
Renal cell carcinoma	Nivolumab	2015	PD-1	-	-	Li et al., 2019b
Hodgkin lymphoma	Nivolumab	2016	PD-1	-	-	Shiravand et al., 2022
Urothelial carcinoma	Atezolizumab	2016	PD-L1	Stage IV NSCLC	Notable improvements in progression-free survival. Investigated in brain metastases	Reck et al., 2020
Head and neck squamous cell carcinoma	Nivolumab	2016	PD-1	-	-	Wei et al., 2018
Head and neck squamous cell carcinoma	Pembrolizumab	2016	PD-1	-	-	Forde et al., 2018

Table 1 (cont.): FDA-approved immune checkpoint inhibitors and their indications across various tumor types

Tumor Type	Therapeutic Agent	FDA Approval Year	Target	FDA-Approved Indications	Additional Information	References
Melanoma (any BRAF status)	Ipilimumab + Nivolumab	2016	CTLA-4, PD-1	-	-	Reck et al., 2020
Non-small cell lung cancer	Atezolizumab	2016	PD-L1	Stage IV Squamous NSCLC	Investigated for neoadjuvant treatment in clinical trials. Associated with improved overall survival	Mazieres et al., 2020
Hodgkin lymphoma	Pembrolizumab	2017	PD-1	-	-	Shiravand et al., 2022
Merkel cell carcinoma	Avelumab	2017	PD-L1	Histologically confirmed metastatic Merkel cell carcinoma	Being explored in combination therapies. Investigated for potential biomarkers of response	Shirley, 2018
Urothelial carcinoma	Avelumab	2017	PD-L1	-	-	Rocco et al., 2022
Urothelial carcinoma	Durvalumab	2017	PD-L1	Stage III non-small-cell lung cancer (NSCLC)	Under investigation for early-stage lung cancer	Paz-Ares et al., 2020
Urothelial carcinoma	Nivolumab	2017	PD-1	-	-	Lin et al., 2018
Urothelial carcinoma	Pembrolizumab	2017	PD-1	-	-	Wei et al., 2018
MSI-high or MMR-deficient solid tumors	Pembrolizumab	2017	PD-1	-	-	Motzer et al., 2018
MSI-high, MMR-deficient metastatic colorectal cancer	Nivolumab	2017	PD-1	-	-	Lin et al., 2018
Pediatric melanoma	Ipilimumab	2017	CTLA-4	-	-	Motzer et al., 2018
Hepatocellular carcinoma	Nivolumab	2017	PD-1	-	-	Wei et al., 2018
Gastric and gastroesophageal carcinoma	Pembrolizumab	2017	PD-1	-	-	Forde et al., 2018
Renal cell carcinoma	Ipilimumab + Nivolumab	2018	CTLA-4, PD-1	-	-	Migden et al., 2018

THE PD-1/PD-L1 AXIS: MECHANISMS OF ACTION AND PATHWAY MODULATION

The PD-1/PD-L1 axis is an essential pathway in the immune system that acts as a key checkpoint, controlling the immune response and upholding immune balance. This axis encompasses the interaction between the programmed cell death protein-1 receptor found on T-cells and its ligand, PD-L1, present on both cancer cells and cells within the tumor microenvironment (Patsoukis et al., 2020).

Discovered in 1992, PD-1 (also known as CD279) is a protein involved in regulating the immune system. Similar to proteins like CD28, CTLA4, and ICOS, PD-1 plays a role in immune function. Its structure includes both an extracellular segment and cytoplasmic tail that are responsible for carrying out signaling functions (Parvez et al., 2023). PD-1 is found on a range of activated immune cells, particularly those infiltrating tumors. Transcription factors such as NFAT, NOTCH, FOX O1, and IRF9 control the expression of the PD-1 gene. While PD-1 is crucial for maintaining immune balance and tolerance, it can also hinder the body's natural response to cancer cells, potentially aiding the progression of tumors (Chen et al., 2023).

The essential protein, PD-L1 serves a crucial function in regulating immune responses. It is produced by a variety of cells, including macrophages, T cells, B cells, dendritic cells, and certain epithelial cells, especially in the presence of inflammation. This protein assists tumors in evading immune surveillance, as highlighted by (Han et al., 2020b). Interestingly, the upregulation of PD-L1 is stimulated by interferon-gamma, which can worsen conditions like ovarian cancer. However, when the IFN- γ receptor is blocked, PD-L1 expression decreases, affecting pathways in acute myeloid leukemia. Additionally, chronic infections can lead to T cell exhaustion, characterized by increased PD-1 expression. This is closely linked to a demethylated promoter region and the influence of transcription factors, such as FOXO1, as outlined by Wu et al. (2019a). Moreover, the secretion of IFN- γ by

both NK cells and T cells not only amplifies the expression of PD-L1 on tumor cells, but also triggers the JAK1, JAK2, and STAT1 pathways, ultimately bolstering the tumor's ability to evade immune surveillance (Padmanabhan et al., 2022).

On top of this, the binding of PD-L1 to its target receptors spurs on cancer cell growth and survival pathways, potentially instigating epithelial-mesenchymal transition and conferring stem cell-like properties that fuel tumor advancement, as observed in cases of renal cancer (Zhou et al., 2023). The immune system is a complex network, and within it, two important proteins, PD-1 and PD-L1, play a critical role in keeping it in balance. These proteins are part of the PD-1/PD-L1 pathway, which helps regulate the body's immune response and maintain a state of immune tolerance. This pathway acts like a checkpoint, safeguarding against autoimmune reactions and ensuring a proper regulation of immune reactions (Yi et al., 2021).

Examining the PD-1/PD-L1 pathway more closely reveals its significance. First and foremost, PD-1 is found on T cells, a crucial component of our immune system responsible for fighting off infections and cancer. On the other hand, PD-L1 is often present on cells within the tumor environment and some normal tissues (Ghosh et al., 2021). When PD-1 on the surface of T cells binds with PD-L1 on other cells, such as cancer cells or antigen-presenting cells, this triggers an inhibitory signal. Essentially, this signal tells the T cells to reduce their activity, which is a normal process in immune regulation. This helps prevent T cells from attacking our own cells and maintains a balanced immune system (Jiang et al., 2019). Cancer cells have a sneaky way of avoiding detection by the immune system. They do so by overexpressing a protein called PD-L1, which binds to another protein on T cells called PD-1, effectively shutting down the immune response (Dong et al., 2018).

Thankfully, there is a way to disrupt this process and unleash the immune system's power to fight back. This can be done through the use of immune checkpoint inhibitors, a

type of drug that blocks the PD-1 and PD-L1 interaction. By inhibiting PD-L1, these medications restore the T cells' ability to attack the cancer cells, providing a potential therapeutic intervention (Wu et al., 2022). The role of the PD-1/PD-L1 pathway in regulating immune tolerance is crucial, as it requires a delicate balance between targeting harmful cells and preserving healthy ones. This intricacy has sparked significant research and has led to the development of advanced cancer treatments that aim to enhance the immune system's ability to fight cancer (Zhou et al., 2022). Modulating the PD-1/PD-L1 pathway involves targeted efforts to disrupt the communication between PD-1 receptors on T-cells and PD-L1 ligands, which are frequently exaggerated on cancer cells and within the tumor microenvironment. This approach aims to bolster the immune system's capacity to combat cancer (Wu et al., 2019a).

Immune checkpoint inhibitors are a class of drugs designed to specifically target and suppress proteins involved in regulating the immune system, such as PD-1 or PD-L1. Through this mechanism, they disrupt the inhibitory signals that typically suppress the immune response, particularly in T cells fighting against cancerous tumors (Lao et al., 2022). Monoclonal antibodies (mAbs) play a crucial role in drug therapy, as they specifically target either PD-1 or PD-L1 to prevent their interaction. For instance, anti-PD-1 mAbs bind to PD-1 receptors on T-cells, while anti-PD-L1 mAbs target PD-L1 ligands present on cancer cells or other cells in the tumor microenvironment (Li et al., 2021). This mechanism makes mAbs an effective treatment option for inhibiting the growth and spread of cancer.

Enhanced T-cell response

By inhibiting the PD-1/PD-L1 interaction, T-cells are able to break free from the restrictive effects of this pathway. This crucial step can reverse the state of T-cell exhaustion and revitalize their ability to multiply and carry out their function. As a result, the immune system can launch a stronger and more effective attack against cancer cells (Barrueto et

al., 2020). When it comes to optimizing treatment outcomes, utilizing a combination of therapeutic approaches has become increasingly common in the use of PD-1/PD-L1 inhibitors. In order to enhance their efficacy, these inhibitors are often paired with other treatments such as chemotherapy, radiation, or other forms of immunotherapy. By combining these treatments, a more conducive environment can be created for the immune system to effectively battle cancer cells (Lee et al., 2022). The advent of PD-1/PD-L1 pathway modulators has revolutionized the approach to treating numerous cancers, bringing about substantial changes in clinical outcomes. Ongoing clinical trials and studies are constantly uncovering the potential of these modulators in various cancer types, with the ultimate goal of enhancing treatment strategies and identifying the most suitable candidates for optimal outcomes (Liu et al., 2022a). Figure 2 depicts the mechanism of PD-1/PD-L1 Inhibitors for reactivation of T cell function.

The manipulation of the PD-1/PD-L1 pathway signifies a calculated change in the way we approach cancer therapy, harnessing the natural power of the immune system to combat disease. This has emerged as a critical focus in the field of oncology research (Liu et al., 2022b). Ultimately, the PD-1/PD-L1 axis plays a crucial role in the immune checkpoint system by maintaining a delicate balance between immunity and self-tolerance, preventing harmful immune reactions while also regulating the body's ability to combat cancer. In light of our understanding of this critical axis, we have developed immunotherapies that specifically target the interaction between PD-1 receptors and PD-L1 ligands, effectively restoring the immune system's ability to identify and destroy cancer cells. These groundbreaking treatments, including monoclonal antibodies and checkpoint inhibitors, have completely revolutionized the field of cancer treatment by significantly boosting the body's immune response against various types of cancer, representing a major milestone in the field of oncology (Somu et al., 2024; Supriya et al., 2024).




Figure 2: Reactivation of T-cell function by PD-1/PD-L1 inhibitors and the role of T-cell receptors, antigens, and MHC

REFINEMENTS IN PD-1/PD-L1 BLOCKADE: RECENT ADVANCES AND DEVELOPMENTS

PD-1 and PD-L1 inhibition is a form of immunotherapy that has transformed the treatment of various cancers. This blockade works by targeting a key regulatory pathway of the immune system, which is often exploited by cancer cells to evade the immune response (Festino et al., 2018). The refinements and recent developments in PD-1/PD-L1 blockade includes firstly the clinical efficacy in melanoma. Advanced melanoma treatment has seen a significant shift with the advent of anti-PD-1 and anti-PD-L1 therapies. The clinical efficacy of PD-1/PD-L1 blockade in the treatment of melanoma represents one of the most significant advancements in the management of this difficult-to-treat cancer (Zhao et al., 2020).

These treatments have led to improved survival rates and are now a cornerstone in the management of metastatic melanoma (Table 2). Prior to the introduction of these immunotherapies, patients with metastatic melanoma faced a very poor prognosis, with median survival times of less than one year (Sundararajan et al., 2022). The emergence of checkpoint inhibitors like nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) has radically improved survival (Gellrich et al., 2020). Data shows that dual therapy with these agents can lead to a 58 % survival rate at three years, which is a significant improvement from historical outcomes (Wolchok et al., 2017). Clinical trials have demonstrated the efficacy of these therapies in increasing patient survival rates and managing disease progression. Key clinical trials that established the efficacy of PD-1 blockers in melanoma include the CheckMate-067 trial (Bari et al., 2022).

Table 2: Mode of action of anticancer agents in melanoma and their correlation with response patterns and safety characteristics

Anticancer Agent	Mechanism of Action	Association with Response Patterns	Safety Profile	Examples	References
BRAF Inhibitors	Inhibit mutated BRAF protein	High response rates in BRAF-mutated melanomas	Common adverse events include rash, fatigue, and arthralgia. Some may lead to secondary skin cancers	Vemurafenib, Dabrafenib	Garutti et al., 2022; Heinzerling et al., 2019
MEK Inhibitors	Target downstream MEK pathway	Often used in combination with BRAF inhibitors	Common side effects include rash, diarrhea, and peripheral edema	Trametinib, Cobimetinib	Garutti et al., 2022; Kakadia et al., 2018
PD-1 Inhibitors	Block PD-1 receptor on T cells	Effective in tumors with high PD-L1 expression	Immune-related adverse events (irAEs) such as colitis, pneumonitis, and thyroid dysfunction	Pembrolizumab, Nivolumab	Okiyama and Tanaka, 2022
CTLA-4 Inhibitors	Block CTLA-4 receptor on T cells	Used alone or in combination with PD-1 inhibitors	Common adverse events include diarrhea, rash, and fatigue. Serious irAEs can occur	Ipilimumab	Wojtukiewicz et al., 2021
Checkpoint Inhibitor Combinations	Simultaneous PD-1 and CTLA-4 blockade	Improved response rates compared to monotherapy	Increased risk of severe irAEs, requiring close monitoring and management	Nivolumab + Ipilimumab	Willsmore et al., 2021
Interferon-alpha	Modulate immune response	Limited efficacy, often used in adjuvant setting	Flu-like symptoms, fatigue, and neuropsychiatric side effects may occur	Interferon-alpha 2b	Xiong et al., 2022
Targeted Therapies (e.g., c-KIT inhibitors)	Inhibit specific signaling pathways	Effective in tumors with specific genetic mutations	Adverse events vary, including gastrointestinal disturbances and fatigue	Imatinib, Dasatinib	Shyam Sunder et al., 2023
Chemotherapy	Inhibit rapidly dividing cells	Considered in advanced or metastatic melanoma	Side effects include myelosuppression, nausea, and hair loss	Dacarbazine, Temozolomide	Anand et al., 2023
Oncolytic Viruses	Replication in cancer cells, causing cell death	Emerging as a novel treatment approach	Generally well-tolerated, with mild flu-like symptoms as common side effects	Talimogene Laherparepvec (T-VEC)	Conry et al., 2018
Immunomodulatory Agents (e.g., IL-2)	Enhance immune response	Reserved for selected cases due to toxicity	Severe side effects, including capillary leak syndrome and organ toxicity, limit its use	Interleukin-2 (IL-2)	Bulgarelli et al., 2021

This study compared nivolumab alone, ipilimumab alone, and the combination of both drugs in patients with advanced melanoma. Results showed that nivolumab alone, as well as in combination with ipilimumab, significantly improved overall survival rates compared to ipilimumab alone (Rager et al., 2022).

Monotherapy vs. combination therapy

While monotherapies using PD-1 inhibitors like pembrolizumab or nivolumab have shown effectiveness, combination therapy regimens pairing nivolumab with ipilimumab have demonstrated even greater benefits in overall response rates and survival, albeit with increased toxicity (Carreau and Pavlick, 2019). Importantly, a subset of melanoma patients treated with PD-1/PD-L1 inhibitors seems to achieve long-term remission, effectively controlling the disease over extended periods. These prolonged responses suggest that PD-1 blockade could potentially offer a form of cure in some cases of advanced melanoma where few treatment options existed before (Chen et al., 2021).

Checkpoint inhibitor mechanism

These drugs work by targeting immune checkpoints. These checkpoints are molecules on certain immune cells which, when activated, can diminish the immune response (Wu et al., 2019b). In the case of PD-1 (programmed death-1), a receptor on T cells, it interacts with PD-L1 (ligand 1), often overexpressed on tumor cells. The essence of PD-1/PD-L1 inhibitors' action is to prevent the exhaustion of T cells, a state where T cells gradually lose their ability to combat cancer cells effectively. When PD-1, present on the T cells, interacts with PD-L1 on tumor cells, the immune response is downregulated, allowing cancer cells to grow and spread. PD-1/PD-L1 inhibitors disrupt this interaction, thereby reinvigorating the T cells to attack and kill tumor cells (Zila et al., 2021; Ai et al., 2020). Initially used for melanoma, PD-1/PD-L1 blockade is now being extended to treat other cancer types. Through ongoing clinical

trials, the use of these inhibitors is approved for various malignancies, including Hodgkin lymphoma, bladder cancer, and many more. Emerging evidence suggests that they might also be effective against traditionally hard-to-treat cancers (Twomey and Zhang, 2021).

Comparison with previous treatments

The emergence of PD-1/PD-L1 blockade therapy represented a paradigm shift in the treatment of metastatic melanoma, surpassing the effectiveness of older treatments like chemotherapy, which had limited impact on long-term survival and often resulted in significant side effects without improving overall survival (Shafi, 2023). Recent research is focusing on the potential synergistic effects of PD-1/PD-L1 inhibitors when combined with other cancer therapies, such as chemotherapy, radiation, and other immunotherapies. These combinations may enhance the immune system's response and address the issue of resistance to single-agent immunotherapy (Yi et al., 2022). Advanced stages of melanoma, which have traditionally been challenging to treat and associated with very poor outcomes, are now being managed more effectively due to these immunotherapeutic agents. The durable responses observed in some patients suggest that these treatments can lead to lasting control of the disease, which was previously unattainable with conventional therapies (Fujimura et al., 2020).

Biomarkers are biological molecules that provide information about a patient's cancer and how it may respond to certain therapies. The search for reliable biomarkers that can predict which patients will benefit from PD-1/PD-L1 blockade is of great interest (Ou et al., 2022). Tumor PD-L1 expression is one of the most extensively studied biomarkers for these inhibitors. The logic is straightforward: if a tumor expresses PD-L1 and thereby weakens the immune response, blocking that pathway could release the "brakes" on the immune system, allowing T cells to target the tumor more effectively. However, PD-L1 expression levels can vary widely and may be influenced by the tumor microenvironment,

and not all patients with PD-L1 positive tumors respond to treatment (Michielin et al., 2020; Zappasodi et al., 2018).

Tumor PD-L1 expression and other factors such as mutational burden and immune cell infiltration within the tumor environment have been evaluated as potential biomarkers (Ma et al., 2022).

Tumor mutational burden

High tumor mutational burden (TMB) has been associated with better responses to immunotherapy, including PD-1/PD-L1 inhibitors. The theory is that tumors with a higher number of mutations may present more neoantigens, which can be recognized as foreign by the immune system, thus targeting the cancer cells more effectively (Chen et al., 2019).

Immune cell infiltrate

The presence and type of immune cells within and around the tumor, often called the immune contexture, can also serve as a biomarker. A "hot" tumor, characterized by a heavy infiltration of T cells, may be more likely to respond to PD-1/PD-L1 blockade than a "cold" tumor with fewer immune cells present (Huang et al., 2021).

However, the predictive value of these markers is not absolute, and researchers are working on identifying and validating additional biomarkers to better select patients for PD-1/PD-L1 inhibitor treatment (Rager et al., 2022). Ongoing research aims to refine and validate biomarkers for PD-1/PD-L1 inhibitor response. This includes looking at combinations of biomarkers and exploring other potential indicators such as specific gene expression patterns, microsatellite instability, and other immune checkpoint molecules (Cohen et al., 2016).

Combining biomarkers

Researchers are investigating the potential of combining different biomarkers to improve the predictive accuracy for treatment response (Song et al., 2023). By using a panel of biomarkers, it might be possible to get a more comprehensive understanding of the tumor

and its relationship with the immune system, leading to better patient stratification and personalized treatment strategies (Islam et al., 2024).

Dynamic changes

It is also recognized that biomarkers can change over time, and what is present at initial diagnosis may not reflect the tumor biology after treatment begins. There is interest in assessing biomarker status at multiple points during treatment to allow dynamic adjustment of therapeutic strategies (Ribas, 2012).

Integrating biomarkers with clinical variables

Another promising area is the integration of biomarker profiles with traditional clinical variables, such as stage of disease and prior treatment history, to develop more robust predictive models for patient response to PD-1/PD-L1 therapies (Auslander et al., 2018).

Overcoming resistance

Some tumors do not respond to PD-1/PD-L1 blockade, or they develop resistance after an initial response. Understanding the mechanisms of resistance is crucial for refining these therapies. Studies are exploring the tumor microenvironment, genetic mutations, and alternative immune checkpoints to find ways to overcome this challenge (Nowicki et al., 2018).

Mechanisms of resistance

Cancer cells may employ various tactics to resist immune checkpoint inhibitors. These mechanisms include alterations in the tumor microenvironment that create an immunosuppressive state, mutations in genes involved in the PD-1/PD-L1 pathway, expression of alternative immune checkpoints, or changes in metabolic pathways affecting immune cell function (Lei et al., 2020).

Research in overcoming resistance

To improve the efficacy of PD-1/PD-L1 inhibitors, research is focusing on understanding these resistance mechanisms. Studies are

exploring the combination of checkpoint inhibitors with other forms of cancer therapy, such as vaccines, targeted therapies, or adoptive cell transfer, to enhance the immune response to cancer cells (Andrews et al., 2020; Goh et al., 2023).

Clinicians are also experimenting with different dosing schedules, combining PD-1/PD-L1 inhibitors with other types of immune checkpoint blockers, and using predictive biomarkers to tailor treatment approaches for each patient as ways to combat resistance (Watson et al., 2020). The goal is to extend the benefits of immunotherapy to more patients and enhance the durability of responses, transforming how we treat various cancers and improving patient outcomes (Zhu et al., 2021). In summary, PD-1/PD-L1 blockade has significantly advanced the field of oncology, offering hope to many patients with hard-to-treat cancers. Ongoing research is focused on not only expanding the use of these therapies to more tumor types but also refining the approach to enhance efficacy, minimize side effects, and ultimately, improve patient outcomes (Mukherjee et al., 2022).

EVALUATING THE EFFICACY: CLINICAL TRIAL INSIGHTS AND PATIENT OUTCOMES

Evaluating the efficacy of PD-1/PD-L1 inhibitors involves assessing their therapeutic impact on cancer, particularly in their role as immunotherapies for conditions like melanoma. The PD-1/PD-L1 pathway is a critical immune checkpoint that, when exploited by cancer cells, can lead to immune evasion. Inhibitors that block this pathway can enhance the immune system's ability to fight cancer (Tang et al., 2018a). The evaluation process for the efficacy of PD-1/PD-L1 inhibitors typically includes the following phases of clinical trial (Tang et al., 2018b):

- ❖ Phase I Trials: To determine the safety, tolerable dose range, and side effects of PD-1/PD-L1 inhibitors when administered to humans. Initial observations regarding efficacy may also be made.

- ❖ Phase II Trials: To assess the effectiveness of the drugs in patients with specific types of cancer and further evaluate the safety profile.

- ❖ Phase III Trials: To confirm the effectiveness of the inhibitors, monitor adverse side effects, and compare their performance to standard treatments.

In PD-1/PD-L1 inhibitor trials, several outcome measures are employed to evaluate the efficacy of the treatment. These typically include the objective response rate, which is the proportion of patients whose tumor size is reduced by a predefined amount for a specified period (Schmidt et al., 2020). Progression-free survival is also measured, indicating the duration patients live without the cancer worsening. Overall survival is a critical metric as well, representing the time from the start of treatment that patients are still alive. In addition to these traditional clinical endpoints, quality of life assessments is often included in trials to gauge the treatment's impact on the daily functioning and well-being of patients. These various outcome measures collectively inform the effectiveness and therapeutic benefit of PD-1/PD-L1 inhibitors in clinical settings (Qin et al., 2024).

Despite often showing promise in clinical trials, there are limitations associated with PD-1/PD-L1 therapy that must be taken into account when evaluating efficacy. Response rates vary with the type of cancer and stage of disease, and some patients may not respond at all or may develop resistance over time (Ou et al., 2022). Furthermore, the balance between immune activation and the risk of immune-related side effects needs to be carefully managed. Biomarkers, such as PD-L1 expression levels, might help predict response but are not always definitive indicators of treatment success. These challenges and considerations highlight the complexity of effectively using PD-1/PD-L1 inhibitors as part of cancer treatment (Zhao et al., 2022). Figure 3 depicts the mechanism of action of PD-1/PD-L1 inhibitors and their role in enhancing anti-tumor immunity.




Figure 3: Mechanism of action: PD-1/PD-L1 inhibitors and their role in enhancing anti-tumor immunity

The expression levels of PD-L1 on tumor cells or in the tumor microenvironment have been studied as potential predictive biomarkers for response to PD-1/PD-L1 inhibitors. However, the predictive power of PD-L1 expression is not absolute, and some patients with high PD-L1 may not respond to therapy while others with low or no expression may still benefit (Ribas, 2012). Other biomarkers, such as tumor mutational burden and mismatch repair deficiency, are also under investigation for their potential to predict responsiveness to immunotherapy. As the field of oncology progresses, genetic profiling of tumors continues to advance, potentially leading to more precise methods for predicting which patients will benefit most from PD-1/PD-L1 inhibitors (Betof Warner et al., 2020).

PD-1/PD-L1 inhibitors can offer sustained advantages to those undergoing treatment, as certain patients may achieve lasting responses that extend the period of cancer management. This underlines the importance of long-term follow-up studies, which are

essential for understanding the full impact of these treatments over time (Yi et al., 2018). Assessing the duration of response helps to evaluate how long the benefits of the therapy last, and whether they translate to improved overall survival and quality of life. The longevity of a favorable response to PD-1/PD-L1 therapy is a key factor in considering the long-term efficacy of these immunotherapeutic agents in the management of various cancers (Herbst et al., 2020).

Real-world effectiveness of PD-1/PD-L1 inhibitors is assessed through observational studies conducted post-approval, which collect data from a broader and more diverse patient population than those typically enrolled in clinical trials (Kumaresan et al., 2022). These studies provide valuable insights into the actual impact of the treatments in routine clinical practice, including their influence on overall survival and long-term health-related quality of life. Such real-world data can reveal effectiveness in a setting that mirrors everyday healthcare conditions, helping to understand how these immunotherapeutic agents

perform outside the tightly controlled constraints of clinical research (Cramer-van Der Welle et al., 2021; Pasello et al., 2020).

While evaluating efficacy, it's equally important to monitor the safety profile and manage potential adverse events that can range from mild skin reactions to severe immune-related complications (Su et al., 2020). Adverse events associated with PD-1/PD-L1 inhibitors can impact a range of organs and systems, reflecting the widespread role of the immune system in the body. The management of these side effects is critical, as they can be life-threatening and may require treatment discontinuation. Pharmacovigilance and post-market surveillance are essential to continually assess the safety profile of these drugs and provide updated guidelines for their use (Kessler and Pandruvada, 2023).

This vigilance helps to balance the potential benefits of therapy against the risks, ensuring patient safety while striving to achieve the best possible treatment outcomes. The high cost of PD-1/PD-L1 inhibitors can impact their accessibility and overall cost-effectiveness. Health economics studies are essential to consider the value these treatments bring relative to their price (Martins et al., 2019). Evaluating the efficacy of PD-1/PD-L1 inhibitors is a complex, multi-step process that takes into account clinical trial data, long-term health outcomes, patient quality of life, and broader health economic factors. Advancements in this field continue to refine our understanding of patient selection and treatment optimization (Yin et al., 2023).

Incorporation of Patient-Reported Outcomes (PRO) is becoming increasingly important in the evaluation of PD-1/PD-L1 inhibitors. These outcomes can give insight into the patients' perspective on symptoms, side effects, and overall impact on their quality of life (King-Kallimanis et al., 2019). Capturing this information is critical as it reflects the real-world experience of patients and helps healthcare providers to tailor treatments to individual needs (Nishijima et al., 2019). Moreover, PRO data contribute to treatment evaluations beyond standard clinical measures,

ensuring that patient satisfaction and subjective well-being are factored into the overall assessment of therapy success. The routine inclusion of PROs in clinical trials and post-marketing surveillance is essential for a holistic understanding of treatment efficacy and patient-centered care (Tykodi et al., 2018).

The future of PD-1/PD-L1 inhibitor efficacy evaluation may lie in a more personalized approach to treatment, where therapy is tailored based on individual patient characteristics and genetic profiles. Evaluating the efficacy of PD-1/PD-L1 inhibitors requires a comprehensive approach that combines clinical trial data, real-world outcomes, and biomarker research for patient selection. Long-term follow-up is crucial for assessing sustained treatment success. The aim is to personalize cancer immunotherapy by integrating clinical, molecular, and genetic data, optimizing treatment efficacy and reducing side effects. PRO are also vital to ensure treatments meet patient needs and improve quality of life (Fitzsimmons et al., 2023). Figure 4 illustrates the multiple pathways for the regulation of PD-1/PD-L1 expression.

CRITICAL DISCUSSION OF THE LIMITATIONS AND POTENTIAL SIDE EFFECTS ASSOCIATED WITH PD-1/PD-L1 CHECKPOINT INHIBITORS

PD-1/PD-L1 checkpoint inhibitors have revolutionized cancer treatment, but they are not without limitations and potential side effects. While PD-1/PD-L1 checkpoint inhibitors have demonstrated remarkable success in some cancer types, a significant challenge remains in the substantial proportion of patients who do not derive clinical benefit from these therapies. This inherent or acquired resistance to PD-1/PD-L1 blockade can arise from a complex interplay of factors, hindering the efficacy of these treatments and necessitating further investigation. Tumor cells with insufficient PD-L1 expression may not be effectively targeted by PD-1/PD-L1 inhibitors (Nowicki et al., 2018). While PD-L1 expression is often used as a biomarker for patient




Figure 4(a): The regulation of PD-1/PD-L1 expression involves multiple pathways. The PI3K/AKT pathway, MAPK pathway, JAK/STAT pathway, WNT pathway, NF-κB pathway, and Hedgehog (Hh) pathway collectively stimulate the expression of the PD-1/PD-L1 axis.




Figure 4(b): Impact of PD-1/PD-L1 immune checkpoint engagement on T-cell fate. The interaction between PD-1 and PD-L1 triggers phosphorylation within PD-1's ITIMs and ITSMs, prompting the association with SHP-2 phosphatase. This interaction inhibits the PI3K/AKT and Ras/MAPK/ERK pathways, culminating in T-cell apoptosis.

selection, its predictive value remains imperfect, and alternative biomarkers are needed. The presence of tumor-infiltrating lymphocytes is crucial for the antitumor activity of checkpoint inhibitors. Tumors with low TIL (tumor-infiltrating lymphocytes) counts, often termed "cold tumors," may not respond effectively to PD-1/PD-L1 blockade. Strategies to enhance T-cell infiltration into the tumor microenvironment are being explored. Tumors can employ various immune-suppressive mechanisms beyond the PD-1/PD-L1 axis. These mechanisms, which may involve other immune checkpoints, immunosuppressive cytokines, or regulatory T cells, can limit the efficacy of PD-1/PD-L1 inhibitors (Zhou et al., 2021). Tumors are often composed of diverse cell populations with varying levels of PD-L1 expression and sensitivity to immune checkpoint blockade. This heterogeneity can contribute to treatment resistance and disease relapse. Even among initial responders, some patients may develop acquired resistance over time. This can occur through the emergence

of new immune-suppressive mechanisms or the selection of resistant tumor cell clones. A particularly concerning limitation of PD-1/PD-L1 blockade is the potential for hyperprogression. This phenomenon, characterized by accelerated tumor growth following treatment initiation, is observed in a subset of patients and can lead to rapid clinical deterioration. The underlying mechanisms of hyperprogression remain poorly understood, and its prediction is challenging. Further research is needed to identify biomarkers that can predict hyperprogression and to develop strategies to mitigate its risk (Champiat et al., 2018; Han et al., 2020a).

Immune-related adverse events (irAEs) are a significant concern with PD-1/PD-L1 inhibitors. These irAEs arise from the enhanced immune activity induced by checkpoint blockade, which, while targeting cancer cells, can also disrupt the delicate balance of the immune system, leading to unintended attacks on healthy tissues and organs (Zheng and Wei 2021). Consequently, irAEs can affect a wide range of organ systems, and their severity can vary significantly. Common immune-related adverse events (irAEs) associated with PD-1/PD-L1 inhibitors can affect various organ systems. Dermatologic irAEs include rash, pruritus, and vitiligo. Gastrointestinal irAEs can manifest as colitis, diarrhea, or hepatitis. Endocrine irAEs may include thyroid dysfunction, hypophysitis, and type 1 diabetes. Pulmonary irAEs such as pneumonitis can also occur. Neurologic irAEs can present as neuropathy or myasthenia gravis (Chuzi et al., 2017; Kumar et al., 2017; Wang et al., 2019; Lee et al., 2020; Ramos-Casals et al., 2020; Yang et al., 2020; Naidoo et al., 2023). While most irAEs are mild to moderate and manageable with appropriate interventions, some can be severe and life-threatening. The management of irAEs often involves a careful balance between controlling the immune-related inflammation and preserving the antitumor efficacy of the checkpoint inhibitors (Brahmer et al., 2018). Corticosteroids, such as prednisone, are commonly used to suppress the immune response and manage irAEs. However,

prolonged use of corticosteroids can have significant side effects and may compromise the antitumor activity of the checkpoint inhibitors. In cases of severe or refractory irAEs, other immunosuppressive agents, such as infliximab or mycophenolate mofetil, may be necessary. Supportive care measures, such as pain management, fluid replacement, and nutritional support, are essential for managing the symptoms of irAEs and promoting patient comfort (Liu et al., 2019; Khan and Monzon 2020). Careful monitoring for the development of irAEs is crucial, and prompt management is essential to minimize their impact on patient outcomes. Early recognition and appropriate intervention can often prevent irAEs from becoming severe or life-threatening (Wood, 2019).

CONCLUSION: THE FUTURE OF PD-1/PD-L1 INHIBITION IN ONCOLOGY PRACTICE

Immunotherapy, particularly the use of PD-1/PD-L1 inhibitors, has become a pivotal aspect of oncological treatment, revolutionizing the management of various cancers. The future of these inhibitors in clinical practice is poised for significant developments. The range of cancers treatable with PD-1/PD-L1 inhibitors is set to broaden as research progresses, potentially standardizing these therapies for a more extensive array of malignancies. A critical factor in the widespread adoption of these agents is the identification of predictive biomarkers to discern responsive patient populations, as the current benefit to patients is variable. Comprehending and overcoming resistance to PD-1/PD-L1 therapies is imperative, and ongoing studies focus on the underlying mechanisms that some tumors exploit to elude these treatments. Optimal management of immune-related adverse events associated with these inhibitors is also a priority, as the prevalence of toxicities may increase with more patients being treated. There are unanswered questions regarding the ideal length of treatment and the feasibility of continuing therapy post-progression, which researchers are actively exploring.

The integration of PD-1/PD-L1 inhibitors with other therapeutic options—including chemotherapy, targeted agents, and additional immunotherapies—is an exciting prospect that could lead to enhanced outcomes. The field is progressively moving towards personalized medicine, aiming to tailor immunotherapeutic interventions to individual tumor profiles and immune system characteristics, which is expected to boost the effectiveness of these agents significantly. Lastly, the financial aspect of PD-1/PD-L1 inhibitor therapies is a growing concern; ensuring these are cost-effective and accessible forms part of the larger dialogue in healthcare economics. In essence, PD-1/PD-L1 inhibition is set to expand its role in oncology, with scientific advances, practical strategies, and novel clinical trials contributing to its evolution, thereby advancing the paradigm of cancer care and fortifying the hope for improved patient prognoses.

REFERENCES

- Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. *DDDT*. 2020;14:3625–49. <https://doi.org/10.2147/DDDT.S267433>.
- Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes Dis*. 2023;10:1367–401. <https://doi.org/10.1016/j.gendis.2022.02.007>.
- Andrews LP, Somasundaram R, Moskovitz J, Szymczak-Workman A, Liu C, Cillo AR, et al. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. *Sci Immunol*. 2020;5(49):eabc2728. <https://doi.org/10.1126/sciimmunol.abc2728>.
- Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. *Nat Med*. 2018;24:1545–9. <https://doi.org/10.1038/s41591-018-0157-9>.

- Bari S, Muzaffar J, Eroglu Z. Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients? *Ther Adv Med Oncol.* 2022;14:175883592210903. <https://doi.org/10.1177/17588359221090306>.
- Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR. Resistance to checkpoint inhibition in cancer immunotherapy. *Transl Oncol.* 2020;13:100738. <https://doi.org/10.1016/j.tranon.2019.12.010>.
- Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. *J Clin Oncol.* 2020;38:1655–63. <https://doi.org/10.1200/JCO.19.01464>.
- Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. *J Oncol Pract.* 2018;14:247–9. <https://doi.org/10.1200/JOP.18.00005>.
- Bulgarelli J, Piccinini C, Petracci E, Pancisi E, Granato AM, De Rosa F, et al. Radiotherapy and high-dose interleukin-2: clinical and immunological results of a proof of principle study in metastatic melanoma and renal cell carcinoma. *Front Immunol.* 2021;12:778459. <https://doi.org/10.3389/fimmu.2021.778459>.
- Carreau NA, Pavlick AC. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. *Future Oncol.* 2019;15:349–58. <https://doi.org/10.2217/fon-2018-0607>.
- Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J-C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. *Nat Rev Clin Oncol.* 2018;15:748–62. <https://doi.org/10.1038/s41571-018-0111-2>.
- Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, et al. Systematic review of PD-1/PD-L1 inhibitors in oncology: from personalized medicine to public health. *The Oncologist.* 2021;26:e1786–99. <https://doi.org/10.1002/onco.13887>.
- Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X. Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune checkpoint blockades. *Front Immunol.* 2019;10:1113. <https://doi.org/10.3389/fimmu.2019.01113>.
- Chen RY, Zhu Y, Shen YY, Xu QY, Tang HY, Cui NX, et al. The role of PD-1 signaling in health and immune-related diseases. *Front Immunol.* 2023;14:1163633. <https://doi.org/10.3389/fimmu.2023.1163633>.
- Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. *Front Oncol.* 2021;11:562315. <https://doi.org/10.3389/fonc.2021.562315>.
- Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. *Cancer Manag Res.* 2017;9:207-13. <https://doi.org/10.2147/CMAR.S136818>.
- Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. *Cancer Immunol Res.* 2016;4:179–82. <https://doi.org/10.1158/2326-6066.CIR-15-0160>.
- Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. *Hum Vaccin Immunother.* 2018;14:839–46. <https://doi.org/10.1080/21645515.2017.1412896>.
- Cramer-van Der Welle CM, Verschueren MV, Tonn M, Peters BJ, Schramel FMNH, Klungel OH, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. *Sci Rep.* 2021;11:6306. <https://doi.org/10.1038/s41598-021-85696-3>.
- Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med.* 2018;50:1-11. <https://doi.org/10.1038/s12276-018-0191-1>.
- Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. *Asia Pac J Oncol Nurs.* 2017;4:127-35. https://doi.org/10.4103/apjon.apjon_4_17.
- Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. *Front Oncol.* 2018;8:386. <https://doi.org/10.3389/fonc.2018.00386>.

- Festino L, Vanella V, Strudel M, Ascierto PA. Molecular mechanisms underlying the action of ipilimumab against metastatic melanoma. In: Hayat MA (ed). Immunology. Vol. 1: Immunotoxicology, immunopathology, and immunotherapy (pp 85-96). Amsterdam: Elsevier, 2018. <https://doi.org/10.1016/B978-0-12-809819-6.00007-1>.
- Fitzsimmons TS, Singh N, Walker TDJ, Newton C, Evans DGR, Crosbie EJ, et al. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. *Front Med.* 2023;10:1192762. <https://doi.org/10.3389/fmed.2023.1192762>.
- Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *N Engl J Med.* 2018;378:1976-86. <https://doi.org/10.1056/NEJMoa1716078>.
- Fujimura T, Kambayashi Y, Ohuchi K, Muto Y, Aiba S. Treatment of advanced melanoma: past, present, and future. *Life.* 2020;10(9):208. <https://doi.org/10.3390/life10090208>.
- Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F. BRAF and MEK inhibitors and their toxicities: a meta-analysis. *Cancers.* 2022;15(1):141. <https://doi.org/10.3390/cancers15010141>.
- Gellrich F, Schmitz M, Beissert S, Meier F. Anti-PD-1 and novel combinations in the treatment of melanoma—an update. *J Clin Med.* 2020;9(1):223. <https://doi.org/10.3390/jcm9010223>.
- Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. *J Cancer.* 2021;12:2735-46. <https://doi.org/10.7150/jca.57334>.
- Goh KW, Stephen A, Wu YS, Sim MS, Batumalaie K, Gopinath SC, et al. Molecular targets of aptamers in gastrointestinal cancers: cancer detection, therapeutic applications, and associated mechanisms. *J Cancer.* 2023;14(13):2491. <https://doi.org/10.7150/jca.85260>.
- Han X, Alu A, Xiao Y, Wei Y, Wei X. Hyperprogression: A novel response pattern under immunotherapy. *Clin Transl Med.* 2020a;10(5):e167. <https://doi.org/10.1002/ctm2.167>.
- Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *Am J Cancer Res.* 2020b;10:727-42.
- He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. *Cell Res.* 2020;30:660-9. <https://doi.org/10.1038/s41422-020-0343-4>.
- Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. *ESMO Open.* 2019;4(3):e000491. <https://doi.org/10.1136/esmoopen-2019-000491>.
- Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study. *J Clin Oncol.* 2020;38:1580–90. <https://doi.org/10.1200/JCO.19.02446>.
- Huang Y-J, Huang C-L, Lai R-Y, Zhuang C-H, Chiu W-H, Lee K-M. Microstructure and biological properties of electrospun in situ polymerization of polycaprolactone-graft-polyacrylic acid nanofibers and its composite nanofiber dressings. *Polymers.* 2021;13:4246. <https://doi.org/10.3390/polym13234246>.
- Immuno-oncology checkpoint inhibitors (Patent). *Nat Biotechnol.* 2022;40:1005. <https://doi.org/10.1038/s41587-022-01392-1>.
- Islam S, Amin MA, Rengasamy KR, Mohiuddin AKM, Mahmud S. Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: a systematic computational approach. *Cancer Med.* 2024;13(15):e70074. <https://doi.org/10.1002/cam4.70074>.
- Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. *Hum Vaccin Immunother.* 2019;15:1111-22. <https://doi.org/10.1080/21645515.2019.1571892>.
- Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Oncotargets Ther.* 2018;11:7095–107. <https://doi.org/10.2147/OTT.S182721>.
- Kessler R, Pandravadra S. Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review. *Oral Oncol Rep.* 2023;6:100036. <https://doi.org/10.1016/j.oor.2023.100036>.
- Khan OF, Monzon J. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. *Curr Oncol.* 2020;27:43–50. <https://doi.org/10.3747/co.27.5111>.

- King-Kallimanis BL, Howie LJ, Roydhouse JK, Singh H, Theoret MR, Blumenthal GM, et al. Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. *Clin Trials*. 2019;16:322–6. <https://doi.org/10.1177/1740774519836991>.
- Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. *Front Pharmacol*. 2017;8(8):49. <https://doi.org/10.3389/fphar.2017.00049>.
- Kumaresan V, Sivaperumal P, Girija AS. Bispecific antibodies targeting tumor-associated metalloprotease and recruit NK cells: a multifunctional therapeutic approach against oral cancer. *Oral Oncol*. 2022;132:106013. <https://doi.org/10.1016/j.oraloncol.2022.106013>.
- Lao Y, Shen D, Zhang W, He R, Jiang M. Immune checkpoint inhibitors in cancer therapy—how to overcome drug resistance? *Cancers (Basel)*. 2022;14:3575. <https://doi.org/10.3390/cancers14153575>.
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*. 2019;381:1535–46. <https://doi.org/10.1056/NEJMoa1910836>.
- Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy. *Immune Netw*. 2022;22(1):e2. <https://doi.org/10.4110/in.2022.22.e2>.
- Lee MY, Jeon JW, Sievers C, Allen CT. Antigen processing and presentation in cancer immunotherapy. *J Immunother Cancer*. 2020;8(2):e001111. <https://doi.org/10.1136/jitc-2020-001111>.
- Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors. *Front Cell Dev Biol*. 2020;8:672. <https://doi.org/10.3389/fcell.2020.00672>.
- Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. *Curr Med Chem*. 2019a;26:3009–25. <https://doi.org/10.2174/0929867324666170804143706>.
- Li B, Jin J, Guo D, Tao Z, Hu X. Immune checkpoint inhibitors combined with targeted therapy: The recent advances and future potentials. *Cancers (Basel)*. 2023;15:2858. <https://doi.org/10.3390/cancers15102858>.
- Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, Leung EL, et al. Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non-small cell lung cancer. *Integr Cancer Ther*. 2019b;18:153473541989002. <https://doi.org/10.1177/1534735419890020>.
- Li Z, Sun G, Sun G, Cheng Y, Wu L, Wang Q, et al. Various uses of PD1/PD-L1 inhibitor in oncology: opportunities and challenges. *Front Oncol*. 2021;11:771335. <https://doi.org/10.3389/fonc.2021.771335>.
- Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. *J Clin Invest*. 2018;128:805–15. <https://doi.org/10.1172/JCI96113>.
- Liu K, Sun Q, Liu Q, Li H, Zhang W, Sun C. Focus on immune checkpoint PD-1/PD-L1 pathway: new advances of polyphenol phytochemicals in tumor immunotherapy. *Biomed Pharmacother*. 2022a;154:113618. <https://doi.org/10.1016/j.biopha.2022.113618>.
- Liu Y, Wang H, Deng J, Sun C, He Y, Zhou C. Toxicity of tumor immune checkpoint inhibitors—more attention should be paid. *Transl Lung Cancer Res*. 2019;8:1125–33. <https://doi.org/10.21037/tlcr.2019.11.26>.
- Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, et al. Research trends and most influential clinical studies on anti-PD1/PDL1 immunotherapy for cancers: a bibliometric analysis. *Front Immunol*. 2022b;13:862084. <https://doi.org/10.3389/fimmu.2022.862084>.
- Ma T, Jiao J, Huo R, Li X, Fang G, Zhao Q, et al. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. *Front Oncol*. 2022;12:922899. <https://doi.org/10.3389/fonc.2022.922899>.
- Maawy AA, Ito F. Future of immune checkpoint inhibitors. In: Ito F, Ernstoff MS: Immune checkpoint inhibitors in cancer (pp 227–43). Amsterdam: Elsevier, 2019. <https://doi.org/10.1016/B978-0-323-54948-6.00012-3>.
- Mansh M. Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. *Yale J Biol Med*. 2011;84:381–9.
- Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019;16:563–580. <https://doi.org/10.1038/s41571-019-0218-0>.

- Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. *J Clin Oncol.* 2020;38:271-80. <https://doi.org/10.1200/JCO.19.01348>.
- Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. *J Immunother Cancer.* 2020;8(2):e000948. <https://doi.org/10.1136/jitc-2020-000948>.
- Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *N Engl J Med.* 2018;379:341-51. <https://doi.org/10.1056/NEJMoa1805131>.
- Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med.* 2018;378:1277-90. <https://doi.org/10.1056/NEJMoa1712126>.
- Mukherjee AG, Wanjari UR, Namachivayam A, Murali R, Prabakaran DS, Ganesan R, et al. Role of immune cells and receptors in cancer treatment: an immunotherapeutic approach. *Vaccines.* 2022;10(9):1493. <https://doi.org/10.3390/vaccines10091493>.
- Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. *J Immunother Cancer.* 2023;11(3):e006398. <https://doi.org/10.1136/jitc-2022-006398>.
- Nishijima TF, Shachar SS, Muss HB, Tamura K. Patient-reported outcomes with PD-1/PD-L1 inhibitors for advanced cancer: A meta-analysis. *The Oncologist.* 2019;24:e565-73. <https://doi.org/10.1634/theoncologist.2018-0449>.
- Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. *Cancer J.* 2018;24:47-53. <https://doi.org/10.1097/PPO.0000000000000303>.
- Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. *Allergol Int.* 2022;71:169-78. <https://doi.org/10.1016/j.alit.2022.01.001>.
- Ou S-L, Luo J, Wei H, Qin X-L, Du S-Y, Wang S, et al. Safety and efficacy of programmed cell death 1 and programmed death ligand-1 inhibitors in the treatment of cancer: an overview of systematic reviews. *Front Immunol.* 2022;13:953761. <https://doi.org/10.3389/fimmu.2022.953761>.
- Padmanabhan S, Gaire B, Zou Y, Uddin MM, Vancurova I. IFN γ -induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. *Cell Signal.* 2022;97:110400. <https://doi.org/10.1016/j.cellsig.2022.110400>.
- Parvez A, Choudhary F, Mudgal P, Khan R, Qureshi KA, Farooqi H, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. *Front Immunol.* 2023;14:1296341. <https://doi.org/10.3389/fimmu.2023.1296341>.
- Pasello G, Pavan A, Attili I, Bortolami A, Bonanno L, Menis J, et al. Real world data in the era of immune checkpoint inhibitors (ICIs): increasing evidence and future applications in lung cancer. *Cancer Treat Rev.* 2020;87:102031. <https://doi.org/10.1016/j.ctrv.2020.102031>.
- Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. *Sci Adv.* 2020;6(38):eabd2712. <https://doi.org/10.1126/sciadv.abd2712>.
- Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. *Ann Oncol.* 2020;31:798-806. <https://doi.org/10.1016/j.annonc.2020.03.287>.
- Qin B, Xin L, Liang C, Li L, Song Q, Long Y, et al. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study. *BMC Cancer.* 2024;24:100. <https://doi.org/10.1186/s12885-024-11833-6>.
- Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. *Mol Cancer.* 2019;18:155. <https://doi.org/10.1186/s12943-019-1091-2>.
- Rager T, Eckburg A, Patel M, Qiu R, Gantiwala S, Dovalovsky K, et al. Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies. *Cancers.* 2022;14:3779. <https://doi.org/10.3390/cancers14153779>.
- Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. *Nat Rev Dis Primers.* 2020;6(1):38. <https://doi.org/10.1038/s41572-020-0160-6>.

- Reck M, Shankar G, Lee A, Coleman S, McClelland M, Papadimitrakopoulou VA, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. *Expert Rev Respir Med.* 2020;14:125-36. <https://doi.org/10.1080/17476348.2020.1701439>.
- Ribas A. Tumor immunotherapy directed at PD-1. *N Engl J Med.* 2012;366:2517-9. <https://doi.org/10.1056/NEJMe1205943>.
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science.* 2018;359:1350-5. <https://doi.org/10.1126/science.aar4060>.
- Rocco D, Della Gravara L, Franzese N, Maione P, Gridelli C. Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going? *Exp Rev Anticancer Ther.* 2022;22:183-9. <https://doi.org/10.1080/14737140.2022.2026772>.
- Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, et al. Immunotherapy in NSCLC: a promising and revolutionary weapon. In: Naing A, Hajjar J (eds). *Immunotherapy* (pp 97-125). Cham: Springer Int. Publ., 2017. (Advances in Experimental Medicine and Biology, Vol. 995). https://doi.org/10.1007/978-3-319-53156-4_5.
- Schmidt EV, Chisamore MJ, Chaney MF, Maradeo MF, Anderson J, Baltus GA, et al. Assessment of clinical activity of PD-1 checkpoint inhibitor combination therapies reported in clinical trials. *JAMA Netw Open.* 2020;3(2):e1920833. <https://doi.org/10.1001/jamanetworkopen.2019.20833>.
- Shafi S. New therapies in melanoma: current trends, evolving paradigms, and future perspectives. *Cutis.* 2023;112(5):E32-9. <https://doi.org/10.12788/cutis.0911>.
- Shao S, Miao H, Ma W. Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs. *Front Immunol.* 2023;14:1295684. <https://doi.org/10.3389/fimmu.2023.1295684>.
- Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. *Curr Oncol.* 2022;29:3044-60. <https://doi.org/10.3390/curroncol29050247>.
- Shirley M. Avelumab: a review in metastatic Merkel cell carcinoma. *Target Oncol.* 2018;13:409-16. <https://doi.org/10.1007/s11523-018-0571-4>.
- Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. *Sig Transduct Target Ther.* 2023;8:262. <https://doi.org/10.1038/s41392-023-01469-6>.
- Somu P, Mohanty S, Basavegowda N, Yadav AK, Paul S, Baek KH. The interplay between heat shock proteins and cancer pathogenesis: a novel strategy for cancer therapeutics. *Cancers.* 2024;16(3):638. <https://doi.org/10.3390/cancers16030638>.
- Song KY, Han YH, Roehrich ME, Brown ME, Torres-Cabala C, Giubellino A. MET receptor tyrosine kinase inhibition reduces interferon-gamma (IFN- γ)-stimulated PD-L1 expression through the STAT3 pathway in melanoma cells. *Cancers.* 2023;15:3408. <https://doi.org/10.3390/cancers15133408>.
- Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, et al. Adverse effects of anti-PD-1/PD-L1 therapy in non-small cell lung cancer. *Front Oncol.* 2020;10:554313. <https://doi.org/10.3389/fonc.2020.554313>.
- Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. *Signal Transduct Target Ther.* 2023a;8:235. <https://doi.org/10.1038/s41392-023-01471-y>.
- Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. *Signal Transduct Target Ther.* 2023b;8:320. <https://doi.org/10.1038/s41392-023-01522-4>.
- Sundararajan S, Thida AM, Yadlapati S, Mukkamalla SKR, Koya S. Metastatic melanoma. In: *StatPearls StatPearls Publ.*, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK470358/>. (accessed February 5, 2024).
- Supriya Y, Sivamalar S, Nallusamy D, Sureka V, Arunagirinathan N, Saravanan S, et al. Application of probiotics in cervical cancer infections to enhance the immune response. *Microb Pathog.* 2024;106764. <https://doi.org/10.1016/j.micpath.2024.106764>.
- Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. *J Clin Invest.* 2018a;128:580-8. <https://doi.org/10.1172/JCI96061>.

- Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. *Nat Rev Drug Discov.* 2018b;17:854–5. <https://doi.org/10.1038/nrd.2018.210>.
- Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. *AAPS J.* 2021;23:39. <https://doi.org/10.1208/s12248-021-00574-0>.
- Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, et al. Patient-reported outcomes with nivolumab in advanced solid cancers. *Cancer Treat Rev.* 2018;70:75–87. <https://doi.org/10.1016/j.ctrv.2018.08.001>.
- Wang H, Mustafa A, Liu S, Liu J, Lv D, Yang H, et al. Immune checkpoint inhibitor toxicity in head and neck cancer: from identification to management. *Front Pharmacol.* 2019;10:1254. <https://doi.org/10.3389/fphar.2019.01254>.
- Wang S, Xie K, Liu T. Cancer immunotherapies: From efficacy to resistance mechanisms – Not only checkpoint matters. *Front Immunol.* 2021;12:690112. <https://doi.org/10.3389/fimmu.2021.690112>.
- Watson GA, Doi J, Hansen AR, Spreafico A. Novel strategies in immune checkpoint inhibitor drug development: how far are we from the paradigm shift? *Br J Clin Pharmacol.* 2020;86:1753–68. <https://doi.org/10.1111/bcp.14355>.
- Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov.* 2018;8:1069–86. <https://doi.org/10.1158/2159-8290.CD-18-0367>.
- Willmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. *Eur J Immunol.* 2021;51:544–56. <https://doi.org/10.1002/eji.202048747>.
- Wojtukiewicz MZ, Rek MM, Karpowicz M, Górska M, Polityńska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. *Cancer Metastasis Rev.* 2021;40:949–82. <https://doi.org/10.1007/s10555-021-09976-0>.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2017;377:1345–56. <https://doi.org/10.1056/NEJMoa1709684>.
- Wood LS. Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types. *J Adv Pract Oncol.* 2019;10(Suppl 1):47–62. <https://doi.org/10.6004/jadpro.2019.10.2.13>.
- Wu G. Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors. *Int J Pharm Sci.* 2021;83:120–6. <https://doi.org/10.36468/pharmaceutical-sciences.757>.
- Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. *J Hematol Oncol.* 2022;15:24. <https://doi.org/10.1186/s13045-022-01242-2>.
- Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, et al. Application of PD-1 blockade in cancer immunotherapy. *Comput Struct Biotechnol J.* 2019a;17:661–74. <https://doi.org/10.1016/j.csbj.2019.03.006>.
- Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition. *Front Immunol.* 2019b;10:2022. <https://doi.org/10.3389/fimmu.2019.02022>.
- Xiong F, Wang Q, Wu G, Liu W, Wang B, Chen Y. Direct and indirect effects of IFN- α 2b in malignancy treatment: not only an archer but also an arrow. *Biomark Res.* 2022;10:69. <https://doi.org/10.1186/s40364-022-00415-y>.
- Yang H, Yao Z, Zhou X, Zhang W, Zhang X, Zhang F. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. *Clin Immunol.* 2020;213:108377. <https://doi.org/10.1016/j.clim.2020.108377>.
- Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. *Mol Cancer.* 2018;17:129. <https://doi.org/10.1186/s12943-018-0864-3>.
- Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. *J Hematol Oncol.* 2021;14:10. <https://doi.org/10.1186/s13045-020-01027-5>.
- Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. *Mol Cancer.* 2022;21:28. <https://doi.org/10.1186/s12943-021-01489-2>.

- Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. *Front Immunol.* 2023;14:1167975. <https://doi.org/10.3389/fimmu.2023.1167975>.
- Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. *Cancer Cell.* 2018;33:581–98. <https://doi.org/10.1016/j.ccell.2018.03.005>.
- Zhang C, Wei F, Ma W, Zhang J. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis. *Front Immunol.* 2024;15:1255825. <https://doi.org/10.3389/fimmu.2024.1255825>.
- Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. *Ther Adv Med Oncol.* 2020;12:175883592093761. <https://doi.org/10.1177/1758835920937612>.
- Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, et al. From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. *Front Immunol.* 2022;13:920021. <https://doi.org/10.3389/fimmu.2022.920021>.
- Zheng X, Wei H. Organ-specific immune-related adverse events for PD-1 antibodies in lung cancer treatment. *Front Oncol.* 2021;11:628243. <https://doi.org/10.3389/fonc.2021.628243>.
- Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. *Front Immunol.* 2021;12:693609. <https://doi.org/10.3389/fimmu.2021.693609>.
- Zhou X, Ni Y, Liang X, Lin Y, An B, He X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. *Front Immunol.* 2022;13:915094. <https://doi.org/10.3389/fimmu.2022.915094>.
- Zhou YJ, Li G, Wang J, Liu M, Wang Z, Song Y, et al. PD-L1: expression regulation. *Blood Sci.* 2023;5:77-91. <https://doi.org/10.1097/BS9.000000000000149>.
- Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. *J Hematol Oncol.* 2021;14:156. <https://doi.org/10.1186/s13045-021-01164-5>.
- Zila N, Hoeller C, Paulitschke V. Novel immune checkpoints beyond PD-1 in advanced melanoma. *Memo.* 2021;14:135–42. <https://doi.org/10.1007/s12254-021-00699-0>.
-